A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

Sanjay Goel, Kavita Desai, Manuel MacApinlac, Scott Wadler, Gary Goldberg, Abbie Fields, Mark Einstein, Fabio Volterra, Benny Wong, Russell Martin, Sridhar Mani

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: GEM®231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1α regulatory subunit of cAMP dependent protein kinase A. Preclinical studies have demonstrated synergistic antitumor activity when GEM®231 is combined with docetaxel. This trial assesses the safety of this combination. Experimental Design: Docetaxel was administered once every three weeks (one-cycle) at doses between 50 - 75 mg/m2. GEM®231 was administered twice weekly at 220 mg/m2 for 3 (schedule-A), or 2 (schedule-B) weeks. Results: Twenty patients with chemotherapy-refractory advanced cancer received a total of 39 cycles of therapy. Six patients in schedule-A received docetaxel 50 mg/m2, and 14 patients in schedule-B received docetaxel 50 - 75 mg/m2. In schedule-A, 2 of 6 patients developed cycle-1 dose limiting toxicity (DLT)-grade-3 fatigue or grade-3 serum transaminase elevation. In schedule-B, 1 of 4 patients developed cycle-1 DLT at the highest dose of docetaxel tested (75 mg/m2)-grade-3 febrile neutropenia. Subsequent dose escalations were not pursued since the overall incidence of grade-3 toxicities (including those that occurred after cycle 1) was 75%, and this dose was close to the single agent MTD of docetaxel. Grade-3 toxicities included fatigue (2 patients), transaminase elevation (4 patients), and altered mentation (1 patient). The mean post-infusion aPTT was significantly higher than the pre-infusion value [14.8 seconds; p<0.001]; however, there were no hemorrhagic episodes. Conclusions: The recommended dose for further development of the combination of docetaxel and GEM®231 is 75 mg/m 2 and 220 mg/m2, respectively. It is important to administer GEM®231 twice weekly for 2 consecutive weeks followed by a one-week break.

Original languageEnglish (US)
Pages (from-to)125-134
Number of pages10
JournalInvestigational New Drugs
Volume24
Issue number2
DOIs
StatePublished - Mar 2006

Fingerprint

docetaxel
Antisense Oligonucleotides
Cyclic AMP-Dependent Protein Kinases
Appointments and Schedules
Safety
Neoplasms
Transaminases
Fatigue
Febrile Neutropenia
GEM231
Research Design

Keywords

  • Antisense
  • Docetaxel
  • Oligonucleotide
  • Phase I
  • Taxane

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers. / Goel, Sanjay; Desai, Kavita; MacApinlac, Manuel; Wadler, Scott; Goldberg, Gary; Fields, Abbie; Einstein, Mark; Volterra, Fabio; Wong, Benny; Martin, Russell; Mani, Sridhar.

In: Investigational New Drugs, Vol. 24, No. 2, 03.2006, p. 125-134.

Research output: Contribution to journalArticle

Goel, Sanjay ; Desai, Kavita ; MacApinlac, Manuel ; Wadler, Scott ; Goldberg, Gary ; Fields, Abbie ; Einstein, Mark ; Volterra, Fabio ; Wong, Benny ; Martin, Russell ; Mani, Sridhar. / A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers. In: Investigational New Drugs. 2006 ; Vol. 24, No. 2. pp. 125-134.
@article{33e45b5e62e741a39781f408c6065d27,
title = "A phase I safety and dose escalation trial of docetaxel combined with GEM{\circledR}231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers",
abstract = "Purpose: GEM{\circledR}231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1α regulatory subunit of cAMP dependent protein kinase A. Preclinical studies have demonstrated synergistic antitumor activity when GEM{\circledR}231 is combined with docetaxel. This trial assesses the safety of this combination. Experimental Design: Docetaxel was administered once every three weeks (one-cycle) at doses between 50 - 75 mg/m2. GEM{\circledR}231 was administered twice weekly at 220 mg/m2 for 3 (schedule-A), or 2 (schedule-B) weeks. Results: Twenty patients with chemotherapy-refractory advanced cancer received a total of 39 cycles of therapy. Six patients in schedule-A received docetaxel 50 mg/m2, and 14 patients in schedule-B received docetaxel 50 - 75 mg/m2. In schedule-A, 2 of 6 patients developed cycle-1 dose limiting toxicity (DLT)-grade-3 fatigue or grade-3 serum transaminase elevation. In schedule-B, 1 of 4 patients developed cycle-1 DLT at the highest dose of docetaxel tested (75 mg/m2)-grade-3 febrile neutropenia. Subsequent dose escalations were not pursued since the overall incidence of grade-3 toxicities (including those that occurred after cycle 1) was 75{\%}, and this dose was close to the single agent MTD of docetaxel. Grade-3 toxicities included fatigue (2 patients), transaminase elevation (4 patients), and altered mentation (1 patient). The mean post-infusion aPTT was significantly higher than the pre-infusion value [14.8 seconds; p<0.001]; however, there were no hemorrhagic episodes. Conclusions: The recommended dose for further development of the combination of docetaxel and GEM{\circledR}231 is 75 mg/m 2 and 220 mg/m2, respectively. It is important to administer GEM{\circledR}231 twice weekly for 2 consecutive weeks followed by a one-week break.",
keywords = "Antisense, Docetaxel, Oligonucleotide, Phase I, Taxane",
author = "Sanjay Goel and Kavita Desai and Manuel MacApinlac and Scott Wadler and Gary Goldberg and Abbie Fields and Mark Einstein and Fabio Volterra and Benny Wong and Russell Martin and Sridhar Mani",
year = "2006",
month = "3",
doi = "10.1007/s10637-006-2378-x",
language = "English (US)",
volume = "24",
pages = "125--134",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

AU - Goel, Sanjay

AU - Desai, Kavita

AU - MacApinlac, Manuel

AU - Wadler, Scott

AU - Goldberg, Gary

AU - Fields, Abbie

AU - Einstein, Mark

AU - Volterra, Fabio

AU - Wong, Benny

AU - Martin, Russell

AU - Mani, Sridhar

PY - 2006/3

Y1 - 2006/3

N2 - Purpose: GEM®231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1α regulatory subunit of cAMP dependent protein kinase A. Preclinical studies have demonstrated synergistic antitumor activity when GEM®231 is combined with docetaxel. This trial assesses the safety of this combination. Experimental Design: Docetaxel was administered once every three weeks (one-cycle) at doses between 50 - 75 mg/m2. GEM®231 was administered twice weekly at 220 mg/m2 for 3 (schedule-A), or 2 (schedule-B) weeks. Results: Twenty patients with chemotherapy-refractory advanced cancer received a total of 39 cycles of therapy. Six patients in schedule-A received docetaxel 50 mg/m2, and 14 patients in schedule-B received docetaxel 50 - 75 mg/m2. In schedule-A, 2 of 6 patients developed cycle-1 dose limiting toxicity (DLT)-grade-3 fatigue or grade-3 serum transaminase elevation. In schedule-B, 1 of 4 patients developed cycle-1 DLT at the highest dose of docetaxel tested (75 mg/m2)-grade-3 febrile neutropenia. Subsequent dose escalations were not pursued since the overall incidence of grade-3 toxicities (including those that occurred after cycle 1) was 75%, and this dose was close to the single agent MTD of docetaxel. Grade-3 toxicities included fatigue (2 patients), transaminase elevation (4 patients), and altered mentation (1 patient). The mean post-infusion aPTT was significantly higher than the pre-infusion value [14.8 seconds; p<0.001]; however, there were no hemorrhagic episodes. Conclusions: The recommended dose for further development of the combination of docetaxel and GEM®231 is 75 mg/m 2 and 220 mg/m2, respectively. It is important to administer GEM®231 twice weekly for 2 consecutive weeks followed by a one-week break.

AB - Purpose: GEM®231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1α regulatory subunit of cAMP dependent protein kinase A. Preclinical studies have demonstrated synergistic antitumor activity when GEM®231 is combined with docetaxel. This trial assesses the safety of this combination. Experimental Design: Docetaxel was administered once every three weeks (one-cycle) at doses between 50 - 75 mg/m2. GEM®231 was administered twice weekly at 220 mg/m2 for 3 (schedule-A), or 2 (schedule-B) weeks. Results: Twenty patients with chemotherapy-refractory advanced cancer received a total of 39 cycles of therapy. Six patients in schedule-A received docetaxel 50 mg/m2, and 14 patients in schedule-B received docetaxel 50 - 75 mg/m2. In schedule-A, 2 of 6 patients developed cycle-1 dose limiting toxicity (DLT)-grade-3 fatigue or grade-3 serum transaminase elevation. In schedule-B, 1 of 4 patients developed cycle-1 DLT at the highest dose of docetaxel tested (75 mg/m2)-grade-3 febrile neutropenia. Subsequent dose escalations were not pursued since the overall incidence of grade-3 toxicities (including those that occurred after cycle 1) was 75%, and this dose was close to the single agent MTD of docetaxel. Grade-3 toxicities included fatigue (2 patients), transaminase elevation (4 patients), and altered mentation (1 patient). The mean post-infusion aPTT was significantly higher than the pre-infusion value [14.8 seconds; p<0.001]; however, there were no hemorrhagic episodes. Conclusions: The recommended dose for further development of the combination of docetaxel and GEM®231 is 75 mg/m 2 and 220 mg/m2, respectively. It is important to administer GEM®231 twice weekly for 2 consecutive weeks followed by a one-week break.

KW - Antisense

KW - Docetaxel

KW - Oligonucleotide

KW - Phase I

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=33646543312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646543312&partnerID=8YFLogxK

U2 - 10.1007/s10637-006-2378-x

DO - 10.1007/s10637-006-2378-x

M3 - Article

VL - 24

SP - 125

EP - 134

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -